Karen M. Anderson Sells 51,160 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 51,160 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $11.88, for a total transaction of $607,780.80. Following the completion of the sale, the insider now directly owns 71,525 shares in the company, valued at approximately $849,717. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Centessa Pharmaceuticals Trading Up 3.2 %

CNTA stock opened at $11.10 on Thursday. The company has a market capitalization of $1.08 billion, a PE ratio of -6.77 and a beta of 1.37. Centessa Pharmaceuticals plc has a 12 month low of $3.52 and a 12 month high of $12.45. The firm’s 50-day moving average is $9.95 and its 200 day moving average is $7.88. The company has a debt-to-equity ratio of 0.29, a current ratio of 9.51 and a quick ratio of 9.51.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC purchased a new position in Centessa Pharmaceuticals in the 1st quarter worth about $25,000. JPMorgan Chase & Co. increased its stake in Centessa Pharmaceuticals by 275.9% in the 4th quarter. JPMorgan Chase & Co. now owns 12,747 shares of the company’s stock worth $39,000 after buying an additional 9,356 shares during the period. Quarry LP purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth about $48,000. Susquehanna International Group LLP purchased a new position in Centessa Pharmaceuticals in the 1st quarter worth about $49,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in Centessa Pharmaceuticals by 371.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock worth $51,000 after buying an additional 5,037 shares during the period. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.